Retinal and choroidal manifestations of systemic medications

Retinal and Choroidal Manifestations of Selected Systemic Diseases

Volumn , Issue , 2013, Pages 479-492

  Schwartz, Stephen G ^a   Mieler, William F ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Crystalline maculopathy; Cystoid macular edema; Diffuse retinal pigment epithelium changes; Retinal and choroidal toxicity; Retinal folds; Subjective visual changes without objective findings; Uveitis; Vascular damage

Indexed keywords

EID: 84905019363     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3646-1_26     Document Type: Chapter

References (80)

1. Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. Arch Ophthalmol. 1957;57: 451-3.
2. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1959;2:478-80.
3. Henkind P, Roth field NF. Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med. 1963;269:433-9.
4. Okun E, Gouras P, Berstein H, von Sallman L. Chloroquine retinopathy. Arch Ophthalmol. 1963;69: 59-71.
5. Brinkley JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol. 1979;88:1-11.
6. Rubin M, Bernstein HN, Zvai fler NJ. Studies on the pharmacology of chloroquine. Arch Ophthalmol. 1963;70:80-7.
7. Ehrenfeld M, Nesher R, Merin S. Delayed-onset chloroquine retinopathy. Br J Ophthalmol. 1986;70: 281-3.
8. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2002;109:1377-82.
9. American Academy of Ophthalmology. Comprehensive adult medical eye evaluation, preferred practice pattern. San Francisco: American Academy of Ophthalmology; 2000.
10. Easterbrook M. Current concepts in monitoring patents on antimalarials. Aust NZ J Ophthalmol. 1998;26:101-3.
11. Flach AJ. Improving the risk-bene fit relationship and informed consent for patients treated with hydroxychloroquine. Trans Am Ophthalmol Soc. 2007;105: 191-4.
12. Rodriguez-Padilla JA, Hedges TR, 3rd Monson B, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007;125:775-80.
13. Kellner U, Renner AB, Tillack H. Fundus auto fluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47: 3531-8.
14. Chang WH, Katz BJ, Warner JE, et al. A novel method for screening the multifocal electroretinogram in patients using hydroxychloroquine. Retina. 2008;28: 1478-86.
15. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415-22.
16. Brinton GS, Norton EWD, Zahn JR, Knighton RW. Ocular quinine toxicity. Am J Ophthalmol. 1980;90: 403-10.
17. Pruzon H, Kiebel G, Maltzman B. Toxic maculopathy part II: a result of quinine usage as demonstrated by fluorescein angiography and electroretinography. Ann Ophthalmol. 1975;7:1475-81.
18. Bacon P, Spalton DJ, Smith SE. Blindness from quinine toxicity. Br J Ophthalmol. 1988;72:219-24.
19. Lochhead J, Movaffaghy A, Falsini B, et al. The effect of quinine on the electroretinograms of children with pediatric cerebral malaria. J Infect Dis. 2003;187: 1342-5.
20. Weekley RD, Potts AM, Reboton J, May RH. Pigmentary retinopathy in patients receiving high doses of a new phenothiazine. Arch Ophthalmol. 1960;64: 65-76.
21. Meredith TA, Aaberg TM, Willerson D. Progressive chorioretinopathy after receiving thioridazine. Arch Ophthalmol. 1978;96:1172-6.
22. Miller III FS, Bunt-Milam AH, Kalina RE. Clinicalultrastructural study of thioridazine retinopathy. Ophthalmology. 1982;89:1478-88.
23. Marmor MF. Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. Br J Ophthalmol. 1980;74:739-42.
24. Chaudhry IA, Shamsi FA, Weitzman ML. Progressive severe visual loss after long-term withdrawal from thioridazine treatment. Eur J Ophthalmol. 2006;16: 651-3.
25. Baath JS, Lam WC, Kirby M, Chun A. Deferoxaminerelated ocular toxicity: incidence and outcome in a pediatric population. Retina. 2008;28:894-9.
26. Mehta AM, Engstrom RE, Kreiger AE. Deferoxamineassociated retinopathy after subcutaneous injection. Am J Ophthalmol. 1994;118:260-2.
27. Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S, Deferoxamine Retinopathy Study Group. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology. 2002;109:164-71.
28. Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single “challenge” dose of deferoxamine. Clin Nephrol. 1989;31:43-8.
29. Lu M, Hansen RM, Cunningham MJ, Eklund SE, Fulton AB. Effects of desferoxamine on retinal and visual function. Arch Ophthalmol. 2007;125:1581-2.
30. Rodriguez AS, Oterino JAM, Fernandez MAF. Unusual toxicity of deferoxamine. Ann Pharmacother. 1999;33:505-6.
31. Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol. 1994;117:772-5.
32. Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol. 2007;144:126-8.
33. Gorin MB, Day R, Constantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493-501.
34. Bourla DH, Gonzales CR, Mango CW, et al. Intravitreous vascular endothelial growth factor (VEGF) inhibitor therapy for tamoxifen induced macular edema. Semin Ophthalmol. 2007;22:87-8.
35. Cortin P, Corriveau LA, Rousseau AP, et al. Maculopathy with golden particles. Can J Ophthalmol. 1982;17:103-6.
36. Boudreault G, Cortin P, Corriveau LA. Canthaxanthine retinopathy: 1. Clinical study in 51 consumers. Can J Ophthalmol. 1983;18:325-8.
37. Chan A, Ko TH, Duker JS. Ultrahigh-resolution optical coherence tomography of canthaxanthine retinal crystals. Ophthalmic Surg Lasers Imaging. 2006;37: 138-9.
38. Weber U, Goerz G, Baseler H, Michaelis L. Canthaxanthin retinopathy. Follow-up of over 6 years. Klin Monbl Augenheilkd. 1992;201:174-7.
39. Stoelting RK, Miller RD. Basics of anesthesia, vol. 64. 2nd ed. New York: Churchill Livingstone; 1989.
40. Bullock JD, Albert DM. Fleck retina. Appearance secondary to oxalate crystals from methoxy flurane anesthesia. Arch Ophthalmol. 1975;93:26-31.
41. Novak MA, Roth AS, Levine MR. Calcium oxalate retinopathy associated with methoxy flurane abuse. Retina. 1988;8:230-6.
42. Withering W. An account of the foxglove, and some of its medical uses: with practical remarks on dropsy and other diseases. London: Robinson; 1785.
43. Weleber RG, Shults WT. Digoxin retinal toxicity. Clinical and electrophysiologic evaluation of a cone dysfunction syndrome. Arch Ophthalmol. 1981;99: 1568-72.
44. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildena fil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164-71.
45. Gabrieli CB, Regine F, Vingolo EM, Rispoli E, Fabbri A, Isidori A. Subjective visual halos after sildenafil (Viagra) administration: electroretinographic evaluation. Ophthalmology. 2001;108:877-81.
46. Luu JK, Chappelow AV, McCulley TJ, Marmor MF. Acute effects of sildena fil on the electroretinogram and multifocal electroretinogram. Am J Ophthalmol. 2001;132:388-94.
47. Tripathi A, O’Donnell NP. Branch retinal artery occlusion: another complication of sildena fil (letter). Br J Ophthalmol. 2000;84:928.
48. Pomeranz HD, Smith KH, Hart WM, Jr Egan RA. Sildena fil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109:584-7.
49. Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf. 2009;32:1-18.
50. Cordell WH, Maturi RK, Costigan TM, et al. Retinal effects of 6 months of daily use of tadala fil or sildena fil. Arch Ophthalmol. 2009;127:367-73.
51. Marmor MF. Sildena fil (Viagra) and ophthalmology. Arch Ophthalmol. 1999;117:518-9.
52. Hayreh MS, Hayreh SS, Baumbach GL, et al. Methyl alcohol poisoning, III: ocular toxicity. Arch Ophthalmol. 1977;95:1851-8.
53. Ingemansson SO. Clinical observations on ten cases of methanol poisoning. Acta Ophthalmol. 1984;62: 15-24.
54. McKellar MJ, Hidajat RR, Elder MJ. Acute ocular methanol toxicity: clinical and electrophysiological features. Aust N Z J Ophthalmol. 1997;25:225-30.
55. AtLee WE. Talc and cornstarch emboli in eyes of drug users. JAMA. 1972;219:49.
56. Tse DT, Ober RR. Talc retinopathy. Am J Ophthalmol. 1980;90:624-40.
57. Martidis A, Yung CW, Ciulla TA. Talc embolism: a static retinopathy. Am J Ophthalmol. 1997;124: 841-3.
58. Friberg TR, Gragoudas ES, Regan CDJ. Talc emboli and macular ischemia in intravenous drug abuse. Arch Ophthalmol. 1979;97:1089.
59. Kresca LJ, Goldberg MF, Jampol LM. Talc emboli and retinal neovascularization in a drug abuser. Am J Ophthalmol. 1979;87:334.
60. Brucker AJ. Disk and peripheral neovascularization secondary to talc and cornstarch emboli. Am J Ophthalmol. 1979;88:864.
61. Gombos GM, Moreno DH, Bedrossian PB. Retinal vascular occlusion induced by oral contraceptives. Ann Ophthalmol. 1975;7:215-7.
62. Petersson GJ, Fraunfelder FT, Meyer SM. Oral contraceptives. Ophthalmology. 1981;88:368-71.
63. Garg SK, Chase P, Marshall G, et al. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA. 1994;271:1099-102.
64. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferonassociated retinopathy. Arch Ophthalmol. 1993;111: 350-6.
65. Nadir A, Amin A, Chalisa N, et al. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J Viral Hepat. 2000;7: 466-70.
66. Tokai R, Ikeda T, Miyaura T, et al. Interferonassociated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119:1077-9.
67. Wei YH, Wang IH, Woung LC, Jou JR. Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immunol In flamm. 2009;17:191-4.
68. Willson RL, Ross RD, Willson LM, et al. Interferonassociated retinopathy in a young, insulin-dependent diabetic patient. Retina. 2000;20:413-5.
69. Han C, O’Day J. Symptomatic interferon retinopathy successfully treated by hypertension management. Br J Ophthalmol. 2007;91:1250-1.
70. Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol. 1973;76:500-10.
71. Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol. 2006;41:197-200.
72. Jampol LM. Niacin maculopathy. Ophthalmology. 1988;95:1704-5.
73. O’Brien DM, Farmer SG, Kalina RE, Leon JA. Acute macular neuroretinopathy following intravenous sympathomimetics. Retina. 1989;9:281-6.
74. El-Dairi M, Bhatti MT, Vaphiades MS. A shot of adrenaline. Surv Ophthalmol. 2009;54:618-24.
75. Desai UR, Sudhamathi K, Natarajan S. Intravenous epinephrine and acute macular neuroretinopathy. Arch Ophthalmol. 1983;111:1026-7.
76. Maddalena MA. Transient myopia associated with acute glaucoma and retinal edema: following vaginal administration of sulfanilamide. Arch Ophthalmol. 1968;80:186-8.
77. Ryan EH, Jampol LM. Drug-induced acute transient myopia with retinal folds. Retina. 1986;6:220-3.
78. Grinbaum A, Ashkenazi I, Avni I, Blumenthal M. Transient myopia following metronidazole treatment for Trichomonas vaginalis. JAMA. 1992;267:511-2.
79. Soylev MF, Green RL, Feldon SE. Choroidal effusion as a mechanism for transient myopia induced by hydrochlorothiazide and triamterene. Am J Ophthalmol. 1995;120:395-7.
80. Banta JT, Hoffman K, Budenz DL, Ceballos E, Green field DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol. 2001;132:112-4.